Sebastian Ciszewski1, Artur Jakimów1, Beata Smolska-Ciszewska2. 1. Urology Department, Regional Medical Center, Opole, Poland; 2. Radiotherapy and Chemotherapy Clinic, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland.
Abstract
INTRODUCTION: We report our 15-year experience of Collecting (Bellini) duct carcinoma (CDC). We retrospectively analyzed patient and tumour characteristics, clinical manifestations, surgical techniques, clinical outcomes, and salvage therapies. METHODS: From January 1999 to December 2013, 1042 patients underwent surgical resection of renal neoplasm. We examined all renal tumors and identified 10 cases (0.96%) of CDC. RESULTS: The study group included 8 men and 2 women, with a median age of 62.5 years. Of these 10 patients, 9 were symptomatic (90%). All patients were treated with open nephrectomy. The mean tumour size was 5.7 cm. The pathologic stages were distributed as follows: pT1b in 2 patients (20%); pT2a in 1 patient (10%); pT3a in 3 patients (30%); and pT3b in 4 patients (40%). Grading was assessed according to Fuhrman scale as follows: grade II in 1 patient (10%); grade III in 3 patients (30%); grade IV in 5 patients (50%); undetermined grade in 1 patient (10%). Four patients (40%) relapsed locally. The median time of local recurrence was 4.9 months. Distant metastases occurred in 9 patients (90%): 4/9 at the time of diagnosis and 5/9 after nephrectomy. The median time of distant metastases after surgery was 8.1 months. Six patients received chemotherapy (gemcitabine plus platinum salts). Radiotherapy was performed in 5 patients. One patient had surgery because of local recurrence and 2 patients were irradiated in the area of the local recurrence. The median overall survival was 7.6 months, and only 2 patients survived more than 2 years after the nephrectomy. CONCLUSIONS: CDCs of the kidney are aggressive and they have a low survival rate. All patients in our study experienced a relapse of their disease. Local recurrence preceded distant metastases. Results of salvage treatments were poor.
INTRODUCTION: We report our 15-year experience of Collecting (Bellini) duct carcinoma (CDC). We retrospectively analyzed patient and tumour characteristics, clinical manifestations, surgical techniques, clinical outcomes, and salvage therapies. METHODS: From January 1999 to December 2013, 1042 patients underwent surgical resection of renal neoplasm. We examined all renal tumors and identified 10 cases (0.96%) of CDC. RESULTS: The study group included 8 men and 2 women, with a median age of 62.5 years. Of these 10 patients, 9 were symptomatic (90%). All patients were treated with open nephrectomy. The mean tumour size was 5.7 cm. The pathologic stages were distributed as follows: pT1b in 2 patients (20%); pT2a in 1 patient (10%); pT3a in 3 patients (30%); and pT3b in 4 patients (40%). Grading was assessed according to Fuhrman scale as follows: grade II in 1 patient (10%); grade III in 3 patients (30%); grade IV in 5 patients (50%); undetermined grade in 1 patient (10%). Four patients (40%) relapsed locally. The median time of local recurrence was 4.9 months. Distant metastases occurred in 9 patients (90%): 4/9 at the time of diagnosis and 5/9 after nephrectomy. The median time of distant metastases after surgery was 8.1 months. Six patients received chemotherapy (gemcitabine plus platinum salts). Radiotherapy was performed in 5 patients. One patient had surgery because of local recurrence and 2 patients were irradiated in the area of the local recurrence. The median overall survival was 7.6 months, and only 2 patients survived more than 2 years after the nephrectomy. CONCLUSIONS: CDCs of the kidney are aggressive and they have a low survival rate. All patients in our study experienced a relapse of their disease. Local recurrence preceded distant metastases. Results of salvage treatments were poor.
Authors: John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani Journal: Am J Surg Pathol Date: 2013-10 Impact factor: 6.394
Authors: G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar Journal: J Pathol Date: 1997-10 Impact factor: 7.996
Authors: Jianmin Wang; Antonios Papanicolau-Sengos; Sreenivasulu Chintala; Lei Wei; Biao Liu; Qiang Hu; Kiersten Marie Miles; Jeffrey M Conroy; Sean T Glenn; Manuela Costantini; Cristina Magi-Galluzzi; Sabina Signoretti; Toni Choueiri; Michele Gallucci; Steno Sentinelli; Vito M Fazio; Maria Luana Poeta; Song Liu; Carl Morrison; Roberto Pili Journal: Oncotarget Date: 2016-05-24
Authors: Sven Wach; Helge Taubert; Katrin Weigelt; Nora Hase; Marcel Köhn; Danny Misiak; Stefan Hüttelmaier; Christine G Stöhr; Andreas Kahlmeyer; Florian Haller; Julio Vera; Arndt Hartmann; Bernd Wullich; Xin Lai Journal: Cancers (Basel) Date: 2019-12-24 Impact factor: 6.639
Authors: Cristina Suarez; David Marmolejo; Augusto Valdivia; Rafael Morales-Barrera; Macarena Gonzalez; Joaquin Mateo; Maria Eugenia Semidey; David Lorente; Enrique Trilla; Joan Carles Journal: Front Oncol Date: 2022-10-04 Impact factor: 5.738
Authors: Dmitry Chernyakov; Alexander Groß; Annika Fischer; Nicola Bornkessel; Christoph Schultheiss; Dennis Gerloff; Bayram Edemir Journal: J Exp Clin Cancer Res Date: 2021-07-07
Authors: Joey El Khoury; Maher Abdessater; Rami Halabi; Fadi Nasr; Johnny Boustany; Anthony Kanbar; Charbel El Hachem; Raghid El Khoury Journal: Case Rep Oncol Med Date: 2020-02-10